Identification of second-generation P2X3 antagonists for treatment of pain.
Bioorg Med Chem Lett
; 28(8): 1392-1396, 2018 05 01.
Article
em En
| MEDLINE
| ID: mdl-29548573
ABSTRACT
A second-generation small molecule P2X3 receptor antagonist has been developed. The lead optimization strategy to address shortcomings of the first-generation preclinical lead compound is described herein. These studies were directed towards the identification and amelioration of preclinical hepatobiliary findings, reducing potential for drug-drug interactions, and decreasing the projected human dose of the first-generation lead.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Dor
/
Piridinas
/
Benzamidas
/
Receptores Purinérgicos P2X3
/
Antagonistas do Receptor Purinérgico P2X
/
Analgésicos
Tipo de estudo:
Diagnostic_studies
/
Prognostic_studies
Limite:
Animals
Idioma:
En
Revista:
Bioorg Med Chem Lett
Assunto da revista:
BIOQUIMICA
/
QUIMICA
Ano de publicação:
2018
Tipo de documento:
Article